News | December 13, 2025
Merck wins key EU backing to expand use of PAH Drug WINREVAIR
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Subscribe To Our Newsletter & Stay Updated
